Stock listing
XLO Stock Price, News, Filings & Events — Xilio Therapeutics, Inc.
Selected listing: XLO · BOATS · USD · US
This page tracks Xilio Therapeutics, Inc.'s XLO:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following XLO:BOATS. XLO:BOATS is the stock-level entry point for investors researching Xilio Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Xilio Therapeutics, Inc. is a public company traded under the ticker XLO in the American market. The company has a market capitalization of approximately $58.4 million. Xilio focuses on developing innovative therapies to improve patient outcomes in cancer treatment.

- Ticker
- XLO:BOATS
- Asset type
- Stock
- Market cap
- $59.2M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- BOATS
- Currency
- USD
Xilio Therapeutics, Inc. XLO:BOATS stock context
This page tracks Xilio Therapeutics, Inc.'s XLO:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following XLO:BOATS. XLO:BOATS is the stock-level entry point for investors researching Xilio Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Xilio Therapeutics, Inc. is a public company traded under the ticker XLO in the American market. The company has a market capitalization of approximately $58.4 million. Xilio focuses on developing innovative therapies to improve patient outcomes in cancer treatment.
Latest news from Xilio Therapeutics, Inc.
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
August 12, 2026
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
June 29, 2026
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
May 12, 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 7, 2026
May 11, 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 7, 2026
Research Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for XLO:BOATS.
Xilio Therapeutics, Inc. company profile
View the public company page for Xilio Therapeutics, Inc. on 6ix.
Xilio Therapeutics, Inc. news
Read company news and market updates connected to Xilio Therapeutics, Inc..
Xilio Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Xilio Therapeutics, Inc..